» Articles » PMID: 36871281

Functional Outcomes After Transanal Total Mesorectal Excision (TaTME): a Random Forest Analysis to Predict Patients' Outcomes

Overview
Date 2023 Mar 5
PMID 36871281
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Anorectal, sexual, and urinary dysfunction are common issues after rectal cancer surgery, although seldom explored. The primary aim of this study was to investigate postoperative anorectal functional results.

Methods: Patients with mid/low-rectal cancer treated with transanal TME (TaTME) with primary anastomosis with/without diverting stoma between 2015 and 2020 were reviewed and selected if they had a minimum follow-up of 6 months (from the primary procedure or stoma reversal). Patients were interviewed using validated questionnaires and the primary outcome was bowel function based on Low Anterior Resection Syndrome (LARS) scores. Statistical analyses were performed to identify clinical/operative variables correlated with worse outcomes. A random forest (RF) algorithm was computed to classify patients at a greater risk of minor/major LARS.

Results: Ninety-seven patients were selected out of 154 TaTME performed. Overall, 88.7% of the patients had a protective stoma and 25.8% reported major LARS at mean follow-up of 19.0 months. Statistical analyses documented that age, operative time, and interval to stoma reversal correlated with LARS outcomes. The RF analysis disclosed worse LARS symptoms in patients with longer operative time (> 295 min) and stoma reversal interval (> 5.6 months). If the interval ranged between 3 and 5.6 months, older patients (> 65 years) reported worse outcomes. Finally, no statistical difference was documented when comparing the rate of minor/major LARS in the first 27 cases versus others.

Conclusion: One-quarter of the patients developed major LARS after TaTME. An algorithm based on clinical/operative variables, such as age, operative time, and time to stoma reversal, was developed to identify categories at risk for LARS symptoms.

Citing Articles

The Review of Modified Intersphincteric Resection in the Treatment of Ultra-Low Rectal Cancer.

Li D, Xiong X, Diao P, Hu J, Niu W, Wang G Curr Treat Options Oncol. 2025; 26(2):84-91.

PMID: 39847237 PMC: 11836164. DOI: 10.1007/s11864-025-01291-y.


Clostridium difficile infection after stoma reversal surgery: a systematic review and meta-analysis of the literature.

Tirelli F, Langellotti L, Lorenzon L, Biondi A, Santoro G, Pezzuto R Int J Colorectal Dis. 2024; 39(1):81.

PMID: 38809269 PMC: 11136761. DOI: 10.1007/s00384-024-04643-6.


Conversion rate to open surgery during transanal total mesorectal excision (TaTME) for rectal cancer: a single-center experience.

Tirelli F, Lorenzon L, Biondi A, Neri I, Santoro G, Persiani R Updates Surg. 2024; 76(3):943-947.

PMID: 38679626 PMC: 11130019. DOI: 10.1007/s13304-024-01844-0.


A systematic review and meta-analysis of minimally invasive total mesorectal excision versus transanal total mesorectal excision for mid and low rectal cancer.

Yong Gang D, Dong L, Dechun Z, Yichi Z, Ya L Front Oncol. 2023; 13:1167200.

PMID: 37377919 PMC: 10291686. DOI: 10.3389/fonc.2023.1167200.

References
1.
Turner B, Cizginer S, Kim M, Mino-Kenudson M, Ducharme R, Surti V . Stent placement provides safe esophageal closure in thoracic NOTES(TM) procedures. Surg Endosc. 2010; 25(3):913-8. PMC: 3312343. DOI: 10.1007/s00464-010-1297-2. View

2.
Filips A, Haltmeier T, Kohler A, Candinas D, Brugger L, Studer P . LARS is Associated with Lower Anastomoses, but not with the Transanal Approach in Patients Undergoing Rectal Cancer Resection. World J Surg. 2020; 45(3):873-879. PMC: 7851016. DOI: 10.1007/s00268-020-05876-6. View

3.
Wasmuth H, Faerden A, Myklebust T, Pfeffer F, Norderval S, Riis R . Transanal total mesorectal excision for rectal cancer has been suspended in Norway. Br J Surg. 2019; 107(1):121-130. DOI: 10.1002/bjs.11459. View

4.
Sturiale A, Martellucci J, Zurli L, Vaccaro C, Brusciano L, Limongelli P . Long-term functional follow-up after anterior rectal resection for cancer. Int J Colorectal Dis. 2016; 32(1):83-88. DOI: 10.1007/s00384-016-2659-6. View

5.
Koedam T, van Ramshorst G, Deijen C, Elfrink A, Meijerink W, Bonjer H . Transanal total mesorectal excision (TaTME) for rectal cancer: effects on patient-reported quality of life and functional outcome. Tech Coloproctol. 2017; 21(1):25-33. PMC: 5285410. DOI: 10.1007/s10151-016-1570-z. View